Page 15 - Crispr News Today

A new treatment for sickle cell disease will change lives — but how many?

An advisory committee is meeting to discuss the potential approval of exagamglogene autotemcel, a CRISPR-based gene editing therapy candidate for sickle cell disease.

The treatment from the company Vertex would be the first medicine to use the gene editing tool CRISPR.

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.

Severe Combined Immunodeficiencies (SCIDs) are a group of debilitating primary immunodeficiency disorders, primarily caused by genetic mutations that disrupt T-cell development. SCID can also affect B-cell and natural killer cell function and counts.

The Cambridge firm is the latest biopharma company in Massachusetts to shed workers in what experts describe as one of the industry’s biggest shakeouts in decades.

Using CRISPR-Cas9, researchers created chickens with increased resistance to avian influenza. But viral mutations arose that may allow replication in human cells.

A new study highlights both the promise and the limitations of gene editing, as a highly lethal form of avian influenza continues to spread around the world.

Plus, has culture come to a standstill?

In portraits by German photographer Herlinde Koelbl, past Nobel laureates convey the essence of their complex research in the palm of their hand.